Hematopoietic stem cells and HSCs-derived from pluripotent stem cells: a hopeful outlook in cell-based therapeutics.

Nowadays, hematopoietic stem cell transplantation (HSCT) and hematopoietic cell transfusion are the accepted therapy for patients with both malignant and nonmalignant hematological disorders. Due to the limited availability of donors and hematopoietic cells, the generation of hematopoietic cells from pluripotent stem cells (PSCs) is considered as a promising alternative source for hematopoietic cells in therapeutic applications. PSCs are undifferentiated cells capable of both self-renewal and differentiation into various hematopoietic lineages, including HSCs, hematopoietic progenitor cells (HPCs), and adult hematopoietic cells in vitro, offer significant potential. Therefore, ex vivo production of patient-specific hematopoietic stem cells (HSCs) derived from renewable sources such as PSCs serves as an experimental tool for investigating the field of regenerative medicine research and can be utilized for treating hematological diseases, especially when no other options are available. This review aims to provide an overview of recent advancements in inducing hematopoietic cells from PSCs, emphasizing the potential implications for future therapeutic interventions.